BACKGROUND: The serum concentration of C-reactive protein (CRP) is mildly elevated in patients with chronic congestive heart failure (CHF), but this level falls well within the range found in healthy subjects. Standard clinical assays for CRP lack sensitivity within the low reference range and thus cannot be used effectively for routine clinical risk prediction. Because assays for high-sensitivity CRP (hsCRP) are now available, we can measure hsCRP to determine its predictive value for the prognosis of patients with CHF. METHODS: Serum levels of hsCRP in 108 patients with CHF and left ventricular ejection fraction (LVEF) <50% were examined. Major adverse cardiac events (death, heart transplantation, or hospitalization with worsening heart failure) during a median follow-up period of 403 days were determined. RESULTS: The concentrations of hsCRP in this study population were significantly increased with the severity of CHF. In a multivariate analysis, LVEF and serum levels of hsCRP were independent significant predictors for adverse outcomes in these patients (hazard ratio, 3.714, P =.024, and hazard ratio, 2.584, P =.047, respectively). However, hsCRP was minimally correlated with LVEF (r = -0.167, P =.084). Further analysis indicated that hsCRP might identify a different high-risk group and could improve risk stratification beyond that of LVEF. CONCLUSIONS: These findings suggest that an elevated level of hsCRP is an independent predictor of prognosis in CHF and can provide additional prognostic information for the risk stratification and treatment in patients with chronic CHF.
BACKGROUND: The serum concentration of C-reactive protein (CRP) is mildly elevated in patients with chronic congestive heart failure (CHF), but this level falls well within the range found in healthy subjects. Standard clinical assays for CRP lack sensitivity within the low reference range and thus cannot be used effectively for routine clinical risk prediction. Because assays for high-sensitivity CRP (hsCRP) are now available, we can measure hsCRP to determine its predictive value for the prognosis of patients with CHF. METHODS: Serum levels of hsCRP in 108 patients with CHF and left ventricular ejection fraction (LVEF) <50% were examined. Major adverse cardiac events (death, heart transplantation, or hospitalization with worsening heart failure) during a median follow-up period of 403 days were determined. RESULTS: The concentrations of hsCRP in this study population were significantly increased with the severity of CHF. In a multivariate analysis, LVEF and serum levels of hsCRP were independent significant predictors for adverse outcomes in these patients (hazard ratio, 3.714, P =.024, and hazard ratio, 2.584, P =.047, respectively). However, hsCRP was minimally correlated with LVEF (r = -0.167, P =.084). Further analysis indicated that hsCRP might identify a different high-risk group and could improve risk stratification beyond that of LVEF. CONCLUSIONS: These findings suggest that an elevated level of hsCRP is an independent predictor of prognosis in CHF and can provide additional prognostic information for the risk stratification and treatment in patients with chronic CHF.
Authors: Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel Journal: Cardiovasc Diagn Ther Date: 2012-06
Authors: Benjamin W Van Tassell; Nayef A Abouzaki; Claudia Oddi Erdle; Salvatore Carbone; Cory R Trankle; Ryan D Melchior; Jeremy S Turlington; Clinton J Thurber; Sanah Christopher; Dave L Dixon; Daniel T Fronk; Christopher S Thomas; Scott W Rose; Leo F Buckley; Charles A Dinarello; Giuseppe Biondi-Zoccai; Antonio Abbate Journal: J Cardiovasc Pharmacol Date: 2016-06 Impact factor: 3.105
Authors: Eric S Williams; Sanjiv J Shah; Sadia Ali; Bee Ya Na; Nelson B Schiller; Mary A Whooley Journal: Eur J Heart Fail Date: 2007-12-21 Impact factor: 15.534
Authors: Ana Savic-Radojevic; Slavica Radovanovic; Tatjana Pekmezovic; Marija Pljesa-Ercegovac; Dragan Simic; Tatjana Djukic; Marija Matic; Tatjana Simic Journal: J Clin Lab Anal Date: 2013-01-24 Impact factor: 2.352
Authors: Bernard Panaszek; Ewa Liebhart; Jerzy Liebhart; Robert Pawłowicz; Andrzej M Fal Journal: Arch Immunol Ther Exp (Warsz) Date: 2007 Sep-Oct Impact factor: 4.291